HUTCHMED (NASDAQ:HCM) Sees Strong Trading Volume – Should You Buy?

HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) saw unusually-strong trading volume on Wednesday . Approximately 30,224 shares changed hands during trading, an increase of 28% from the previous session’s volume of 23,643 shares.The stock last traded at $13.29 and had previously closed at $13.40.

Analyst Ratings Changes

Several research firms have weighed in on HCM. Wall Street Zen raised HUTCHMED from a “hold” rating to a “buy” rating in a research report on Sunday, November 16th. Zacks Research downgraded shares of HUTCHMED from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 9th. Morgan Stanley lowered shares of HUTCHMED from an “equal weight” rating to an “underweight” rating and reduced their price target for the company from $18.00 to $13.75 in a research report on Monday, September 22nd. Finally, Weiss Ratings restated a “hold (c)” rating on shares of HUTCHMED in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $20.88.

HUTCHMED Stock Performance

The company has a debt-to-equity ratio of 0.05, a quick ratio of 4.51 and a current ratio of 4.65. The business has a 50-day moving average price of $14.23 and a 200 day moving average price of $15.49.

Hedge Funds Weigh In On HUTCHMED

Large investors have recently modified their holdings of the business. Jane Street Group LLC boosted its holdings in HUTCHMED by 128.0% in the 1st quarter. Jane Street Group LLC now owns 222,241 shares of the company’s stock worth $3,343,000 after buying an additional 124,771 shares during the period. UBS Group AG raised its holdings in HUTCHMED by 112.8% during the 3rd quarter. UBS Group AG now owns 137,000 shares of the company’s stock valued at $2,158,000 after acquiring an additional 72,614 shares during the period. Amundi lifted its position in shares of HUTCHMED by 41.9% during the third quarter. Amundi now owns 223,330 shares of the company’s stock worth $3,620,000 after acquiring an additional 65,898 shares in the last quarter. ABN Amro Investment Solutions bought a new position in shares of HUTCHMED in the second quarter worth $962,000. Finally, Tema Etfs LLC purchased a new position in shares of HUTCHMED in the second quarter valued at $641,000. Hedge funds and other institutional investors own 8.82% of the company’s stock.

About HUTCHMED

HUTCHMED (NASDAQ: HCM) is a fully integrated biopharmaceutical company focused on discovering, developing, manufacturing and commercializing targeted therapies and immunotherapies for the treatment of cancer and other diseases. The company leverages in-house capabilities in small-molecule chemistry, biologics engineering and translational medicine to advance candidates through all stages of development. HUTCHMED’s integrated model encompasses early discovery research, clinical development, regulatory filings and commercial launches, enabling seamless progression from laboratory to market.

HUTCHMED’s commercial portfolio includes several in-market oncology therapies approved in China, including fruquintinib for metastatic colorectal cancer, surufatinib for neuroendocrine tumors and savolitinib for non-small cell lung cancer.